Thrombocytopenia Treatment Market: By Drug Class (Lysosomal Enzyme, Platelet Stimulating Agents, and Glucocorticoids), By Disease Indication (Leukemia, Hemolytic Uremic Syndrome, Immune Thrombocytopenia, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography.  

Thrombocytopenia Treatment Market size was valued at USD 5.2 billion in 2023 and is poised to grow at a significant CAGR of 6.2% from 2024-2030. The root cause of thrombocytopenia are the platelet splenic sequestration, inefficiency in the production of the platelets and the destruction of the platelets. The Thrombocytopenia Treatment Market is either inherited or acquired. It usually occurs owing to various disorders such as leukemia and immune system related conditions. This is commonly found in both adults and children. In thrombocytopenia condition show very less symptoms and is mild. In some cases, the count of the platelets is so low that it causes dangerous internal bleeding, as the patient affected with thrombocytopenia leads to delayed blood clotting or sometimes no blood clotting.

Key Developments: 

In February 2018, Shionogi & Co., Ltd announced that the New Drug Application (NDA) for lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, has been accepted for filing and has been granted Priority Review by the U.S. Food & Drug Administration (FDA).